Abstract
Introduction
Pentraxins are a superfamily of evolutionarily conserved proteins originally named for their structural organization characterized by a radial pentameric structure. Pentraxins are divided into two subfamilies Cardiovascular Medicine [1] . Long-pentraxins differ from short-pentraxins for the presence of an unrelated N-terminal domain coupled to the C-terminal domain [2] (Fig. 1) .
C-reactive protein (CRP) and serum amyloid P component (SAP) constitute the short-pentraxin arm of the superfamily. These "classical" pentraxins are acute phase proteins in man and mouse, respectively, and are produced in liver in response to inflammatory mediators, most prominently interleukin-6 (IL-6) [3, 4] . They are involved in the innate resistance to microbes and scavenging of cellular debris and extracellular matrix (ECM) components [1, [5] [6] [7] .
Pentraxin 3 (PTX3, also called is the prototypic member of the long-pentraxin subfamily [8, 9] that includes also guinea pig apexin, rat, human, and murine neuronal pentraxins 1 (NP1 or NPTX1) and NP2 (also called Narp or NPTX2), and the putative integral membrane pentraxin NRP (see [1] [10] . Long-pentraxins have been found in Xenopus (XL-PXN1) [2] and in Drosophila melanogaster [11] . Also, PTX3, NP1, NP2, and NPR orthologs have been identified in zebrafish [1] .
for a recent review). NP1 and Narp may form mixed pentraxin assemblies that play a role in excitatory synaptic plasticity in developing and adult brain
PTX3 is a soluble pattern recognition receptor with unique non-redundant functions in various physiopathological conditions [12] . Unlike short-pentraxins, PTX3 is synthesized locally at the inflammatory site by mononuclear phagocytes [13] , myeloid dendritic cells [14] , fibroblasts [9] , adipocytes [15] , granulosa cells [16] , mesangial cells [17, 18] , smooth muscle cells (SMCs) [8] and endothelial cells [8] . PTX3 expression is upregulated in mice during inflammation [19, 20] and the levels of circulating PTX3 increase in several pathological conditions affecting the cardiovascular system, including vasculitides [21] , acute myocardial infarction [22] , rheumatoid arthritis [23] , and systemic inflammatory response syndrome/septic shock [24] .
Like "classical" pentraxins, PTX3 binds the complement component C1q, leading to activation of the classical complement pathway [25] . PTX3 binds also apoptotic cells, selected pathogens, ECM components and angiogenic growth factors (Table 1) . PTX3 transgenic mice show improved survival to endotoxemia and sepsis [26] . Conversely, PTX3 -/-mice show defective resistance against selected pathogens [27] . Also, PTX3 -/-mice show an alteration in seizureinduced damage in the central nervous system [20] and deficient women are sub-fertile [16] . Taken together, the data indicate that PTX3 may serve as a mechanism of amplification of inflammation and innate immunity, tightly related to endothelial cell functions (Fig. 2) . Here, the biochemical and biological properties of PTX3 will be reviewed in the context of its role in vascular biology. [25, 47, [53] [54] [55] C1s no [25] Short-pentraxin ligands phosphorylcoline no [25] phosphoethanolamine no [25] high pyruvate agarose no [25] histones yes [25, 44] Isolated microbial components zymosan yes [48] KpOmpA yes [51] ECM components hyaluronic acid no [35] TSG6 yes [35] heparin/HSPGs no * type IV collagen no [25, 44] fibronectin no [25, 44] vitronectin no [44] Eukariotic cell surfaces/receptors apoptotic cell extranuclear membrane yes [82] A-type K(+) channel yes [105] integrins no * gangliosides no * HSPGs no *
PTX3 gene and expression

Growth factors/ cytokines/ chemokines
FGF2 yes [44] FGF1 no [44] FGF4 no [44] FGF8 weak [44] VEGF weak [44] NGF no [44] M-CSF no [44] TNF no [44] IL-1 no [44] IL-4 no [44] IL-6 no [44] IL-8 no [44] IL-10 no [44] IL-12 no [44] MCP-1 no [44] lymphotactin no [44] * M. Rusnati, unpublished observations. antagonist, or by a combination of the two agents [23] . [18] . Finally, IL-1␤ and TNF␣ induce PTX3 expression in human lung epithelial cells via the JNK pathway [36, 37] . [38, 39] [40, 41] . [19] . Finally, intratracheal instillation of LPS, that induces acute lung injury in mice, is associated with a significant increase of PTX3 expression in the bronchoalveolar lavage fluid and in the lung tissue [37] .
Vascular endothelial cells and SMCs produce abundant amounts of PTX3 in response to inflammatory signals. Beside IL-1␤ and LPS, oxidized and enzymatically degraded low density lipoproteins (LDL) promote PTX3 production by human primary vascular SMCs
(see below for further details about PTX3 expression in atherosclerosis). Statins inhibit PTX3 gene expression in human umbilical vein endothelial cells and SMCs, but not in hepatocarcinoma cells [40]. Since PTX3 plays a pivotal role in thrombogenesis and ischaemic vascular disease (see below), PTX3 down-regulation may contribute to the reduction of the risk of cardiovascular diseases by statins
In vivo, PTX3 gene expression is induced by LPS in a variety of organs in mice. In particular, PTX3 is produced by the vascular endothelium of skeletal and cardiac muscle. Unlike neuronal long-pentraxins, PTX3 is not constitutively expressed by the central nervous system. However, injection into the cerebral ventricles of LPS, IL-1␤ and TNF␣ induces local expression of PTX3. Interestingly, LPS and IL-1␤ also induce high levels of PTX3 expression in the heart
PTX3 protein structure
The human PTX3 protomer is a 381 amino acid glycoprotein, including a 17 amino acid signal peptide for secretion. PTX3 primary sequence is highly conserved among animal species (human and murine PTX3 sharing 92% of conserved amino acid residues), suggesting a strong evolutionary pressure to maintain its structure-function relationships [1] .
As the other members of the long-pentraxin subfamily, PTX3 is composed of an unique N-terminal domain (spanning amino acid residues 1-178) and of a Cterminal 203 amino acid domain highly homologous among the various members of the pentraxin family (57% of conserved amino acids with short-pentraxins CRP and SAP).
No crystallographic data are available for the Nterminal portion of long-pentraxins. We performed consensus secondary structure prediction of PTX3 N-terminus [42] . Four ␣-helix regions connected by short loops have been identified that span amino acid residues [42] .
The N-terminal sequence of PTX3 contains three cysteine residues in positions 47, 49, and 103 . Three cysteine residues are present also in the N-terminal coiled-coil ␣-helices of the human long-pentraxins NP1 and NP2 in the positions 16, 26, 73 and 14, 26, 79, respectively [10] . These residues are engaged in inter-chain disulphide bonds, thus providing stability to the multimeric status of NP1 and NP2 [10] [45] . This structural similarity well matches with the role of these collectins and of PTX3 as humoral components of the innate immune system [45] . The high similarity of the primary sequence of the PTX3 C-terminus with short-pentraxins allowed to produce a predicted structure for the C-terminal PTX3 region (residues 179-381) using the crystallographic structure of CRP as template (PDB code: 1B09) . The model of PTX3 C-terminus presents a hydrophobic core composed by two anti-parallel ␤-sheets organised in a typical ␤-jelly roll topology (Fig. 3C) . A similar model was described when PTX3 was modelled on the tertiary structure of SAP [46] C-terminal domain [47] . Table 1 ). However, PTX3 interaction with A. fumigatus is competed by galactomannan [27] . This is consistent with the capacity of PTX3 to interact with zymosan [48] , a complex carbohydrate of the yeast cell wall composed mainly by mannan and ␤-glucan. [48] . Zymosan is known also to affect endothelial permeability in a complement-independent manner [50] . Thus [52] . The complement fraction C1q was the first characterized PTX3 ligand [25] . More recently, the interaction of PTX3 with the whole C1 complex, but not with the fraction C1s [25] , has been reported [53] [53] . In contrast, the binding of C1q to PTX3 in the fluid phase prevents the formation of C1q/immunoglobulin complexes, complement activation, and hemolytic activity [53, 55] 
between the N-terminal region of PTX3 and the N-terminal domain of the members of the collectin family, including the mannose-binding protein (MBP) and the surfactant proteins A and D (SP-A and SP-D)
Zymosan induces inflammatory signals in macrophages following recognition by dectin-1 and the Toll-like receptors TLR2 and TLR6 [49]. PTX3 interaction increases the clearance of zymosan particles by macrophages in a dectin-1-dependent manner [48]. Accordingly, PTX3 functions as an opsonin for the yeast cell form of the fungal pathogen Paracoccidioides brasiliensis
As a consequence of this interaction, PTX3 may modulate the proinflammatory program triggered by K. pneumoniae in endothelial cells
. Since a crosstalk exists between the complement system and endothelial cells in different physiological conditions and in vascular diseases [56], these observations suggest that PTX3 may differently regulate endothelial cell functions depending upon its free or immobilized status. Indeed, besides its presence in blood as a circulating protein, PTX3 can be detected in the ECM [35, 39], raising the question of the ECM component(s) binding to PTX3.
PTX3 does not bind type IV collagen, fibronectin, and gelatin, all ECM ligands for short-pentraxins [25] . [35] . Through this mechanism, PTX3 plays a key role in the assembly of the ECM of the cumulus oophorus, essential for female fertility [35] . Interestingly, HA and TSG6 are also present in the endothelial microenvironment where they regulate different aspects of endothelial cell biology [57] [58] [59] M depending upon the experimental model adopted [42, 44] .
In contrast, PTX3 binds the TNF␣-induced protein 6 (TNFAIP6 or TSG6) that, in turn, binds hyaluronic acid (HA). This leads to the formation of multimolecular PTX3/TSG6/HA complexes, even though no direct interaction occurs between PTX3 and HA
In agreement with the incapacity of short-pentraxins to bind FGF2 [44] , the FGF2-binding domain of PTX3 has been located in its N-terminal region [42] . Accordingly, C1q does not compete for FGF2 binding to PTX3 [7] .
Also, glycosilation of PTX3, which is involved in PTX3/C1q interaction (see above), does not affect PTX3/FGF2 interaction (M. Camozzi, unpublished observations). An integrated approach that utilized PTX3-related synthetic peptides, monoclonal antibodies, and surface plasmon resonance analysis has identified the FGF2-binding domain in the PTX3(97-110) amino acid sequence within the PTX3 N-terminus (see above) [42]. These observations point to a novel unanticipated function for the Nterminal extension of PTX3. At the functional level, PTX3/FGF2 interaction prevents the binding of the growth factor to its cell surface receptors, thus inhibiting its biological activity in target cells. Accordingly, PTX3, but not short-pentraxins, suppresses the pro-angiogenic and prorestenotic activity exerted by FGF2 on endothelial cells and SMCs, respectively (see below).
It has been demonstrated that PTX3 can directly stimulate endothelial cells and macrophages [41, 60] [61] . [62] and the identification of such modules in a given protein may give clues about its functional properties [63] . A significant module homology has been observed among short-pentraxins, laminin, and thrombospondin (TSP) [63] . Relevant to this point, PTX3 and TSP share the capacity to exist either as circulating or ECM-associated proteins and are both involved in the regulation of endothelial cell integrity and angiogenesis. Accordingly, they bind FGF2 and inhibit its biological activity with similar affinity and mechanism of action [64, 65] . Further studies are awaited to map the binding regions in the PTX3 molecule responsible for the interaction with its various ligands.
Taken together, experimental evidences indicate that PTX3 is a modular protein able to interact with various ligands via its N-terminal or C-terminal domains. Module exchange has played a major role during protein evolution in eukaryotic cells
PTX3 in vascular pathology
PTX3 as a marker of vascular damage
Vessel wall elements produce high levels of PTX3 during inflammation. Thus, when compared to the liver-produced short-pentraxin CRP, PTX3 may represent a rapid marker for primary local activation of inflammation as well as of innate immunity. Indeed, blood levels of PTX3 rise dramatically in inflammatory conditions from <2 ng/ml up to 200-800 ng/ml during active disease [1] . This occurs very rapidly when compared to the increase of CRP levels, consistent with the original identification of PTX3 as an immediate early gene [22] .
Increased levels of PTX3 have been observed in diverse infectious disorders, including sepsis, A. fumigatus infections, tuberculosis, and dengue [24, 27] , in the synovial fluid in rheumatoid arthritis [23] , and in plasma of untreated psoriatic patients [66] . In some of these conditions, PTX3 levels correlate with disease activity or severity. PTX3 levels increase also in preeclampsia, possibly as a consequence of the endothelial dysfunction that characterizes this syndrome [67, 68] . PTX3 levels peak in plasma early after myocardial infarction (approximately after 6-8 hrs) [22] , thus representing an independent predictor of mortality when measured within the first day from the onset of symptoms [69] . The presence of PTX3 in infarcted hearts and the higher degree of ischaemic injury in hearts of PTX3 -/-mice support a pathophysiologic role of the protein in myocardial damage and repair [69] . [70] . PTX3 is abundantly present in endothelial cells of skin biopsies from patients with active vasculitis [21] . Also, in keeping with the inhibitory effect exerted by PTX3 on the phagocytosis of late apoptotic polymorphonuclear leukocytes by macrophages [71] , PTX3 is overexpressed at sites of leukocytoclastic vasculitis lesions [72] 
Small-vessel vasculitides represent a group of disorders characterized by inflammatory damage of the vessel wall consequent to immunopathogenic mechanisms and primary inflammatory cytokines
Atherosclerosis
An increasing body of evidence point to the inflammatory nature of the atherosclerotic process [73] . Plasma levels of the classical short-pentraxin CRP correlate with increased risk of cardiovascular disease [74] and subendothelial deposition of CRP has been detected in atherosclerotic lesions, possibly as the consequence of its passive transudation from circulation to the extravascular space [75] [80] or by T lymphocytes that infiltrate the atherosclerotic plaque [81] . Also, PTX3-mediated opsonization of apoptotic cells may contribute to the clearance of lipid-loaded macrophages and foam cells by dendritic cells [82] . Finally, PTX3 may play a role in the progression of the advanced atherosclerotic lesions by stimulating the production of tissue factor by endothelium [60] and activated monocytes [41] , thus favoring clotting activation and thrombogenesis (Fig. 2) . More data are required to define the role of PTX3 in the modulation of the atherosclerosis disease process.
Angiogenesis
Angiogenesis is the process of generating new capillary blood vessels. Uncontrolled neovascularization occurs during tumor growth and atherosclerosis and plays a pivotal role in inflammation [83] . Angiogenesis is controlled by the balance between pro-and anti-angiogenic factors [84] .
FGF2 is a prototypic heparin-binding angiogenic growth factor that induces cell proliferation, chemotaxis, and protease production in cultured endothelial cells by interacting with high affinity tyrosine-kinase receptors (FGFRs) [85] . FGF2 induces angiogenesis in vivo and modulates neovascularization during tumor growth, wound healing, inflammation, and atherosclerosis [86] . FGF2 is produced by various tumor and normal cell types, including cells involved in inflammation and immunity like mononuclear phagocytes [87] , T lymphocytes [81] , and endothelial cells [88] . Also, FGF2 production and release is modulated by inflammatory mediators (e.g. IL-2 [89] and nitric oxide [90] ), hypoxia [87] , and cell damage [91] . Thus 
Restenosis
Percutaneous transluminal coronary angioplasty is commonly used to repair occluded atherosclerotic blood vessels, but its long-term efficacy is limited by restenosis [93] that leads to recurrent acute coronary events and even death [94] .
The process of restenosis starts with the disruption of the endothelial layer followed by SMC migration and proliferation [95] . The FGF/FGFR system plays an important role in SMC activation in vitro and in vivo following arterial injury. Indeed, FGF2 promotes survival, proliferation, and migration of SMCs [96] [97] [98] [99] that express FGFRs [100] . FGFs are expressed in injured arteries and contribute to intimal thickening [101, 102] . Accordingly, arterial injury leads to FGFR upregulation in SMCs [101, 103] . PTX3 inhibits the biological activity exerted by FGF2 on SMCs in vitro and in vivo [104] 
